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The objective of this study was to analyze the level of evidence regarding the efficacy, effectiveness and 
safety of over-the-counter (OTC) cough medications registered in Brazil. The National Health Surveillance 
Agency database was used to identify the drugs. Clinical trials, systematic reviews, meta-analyses, and 
studies on safety were searched on the Medline baseline, the Cochrane Library and SIETES (System of 
Essential Information in Therapeutics and Health; database in Spanish). Most drugs (62.5%) were sold 
as a fixed-dose combination of two or more drugs. Randomized clinical trials were found for only three 
drugs: bromhexine, dextromethorphan and guaifenesin. No clinical trials were found for fixed-dose 
combinations. Systematic reviews on Cochrane did not report any evidence in favor of or against the 
effectiveness of cough drugs. Efficacy is also unclear, especially regarding fixed-dose combinations. 
The evidence for the efficacy of OTC cough medications available in Brazil is poor due to the lack of 
quality studies. Pharmacovigilance of OTC cough medications should be encouraged.
Uniterms: Drugs/utilization studies. Cough. Drugs/nonprescription. Pharmacovigilance. 
Pharmacoepidemiology.
O objetivo deste trabalho foi analisar o nível de evidências sobre a eficácia, a efetividade e a segurança 
dos medicamentos para tosse registrados no Brasil. A base de dados da Agência Nacional de Vigilância 
Sanitária foi empregada para identificar os medicamentos. Os ensaios clínicos, as revisões sistemáticas, 
as metanálises e os estudos de segurança foram pesquisados no Medline, the Cochrane Library e SIETES 
(Sistema de Informações Essenciais em Terapêutica e Saúde, base de dados em espanhol). A maioria 
dos medicamentos (62,5%) eram comercializados como associação em dose fixa com dois ou mais 
fármacos. Ensaios clínicos randomizados foram encontrados apenas para três fármacos: bromexina, 
dextrometorfano e guaifenesina; para associações a dose fixa não foram encontrados ensaios clínicos. 
Revisões sistemáticas publicadas pela Cochrane não encontraram evidências favoráveis ou contrárias à 
efetividade dos medicamentos para tosse. Essa eficácia não é clara, especialmente a das associações a 
dose fixa. As evidências sobre a eficácia dos medicamentos para tosse isentos de prescrição disponíveis 
no mercado brasileiro são fracas, devido à falta de pesquisas de boa qualidade. A farmacovigilância de 
medicamentos para tosse isentos de prescrição deve ser incentivada.
Unitermos: Medicamentos/estudos de utilização. Tosse. Medicamentos/isentos de prescrição. 
Farmacovigilância. Farmacoepidemiologia.
INTRODUCTION
Acute cough is a common symptom, usually asso-
ciated with viral and bacterial infections of the respiratory 
tract, and is one of the most common reasons for seeking 
medical care services, especially in pediatrics (Schaefer 
et al., 2007; Kelley, Allen, 2007). The common cold 
and acute cough are important determinants of access to 
drugs for self-medication. The magnitude of such use is 
evidenced by studies showing that about 95 million units 
of pediatric drugs for coughs and colds are sold every year 
in the United States (Sharfstein et al., 2007). The sale of 
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pediatric and adult cough medication represents a signi-
ficant proportion of the pharmaceutical market in many 
countries (Morice, 2002; Sharfstein et al., 2007). In most 
countries, these pharmaceutical preparations are sold as 
over-the-counter (OTC) drugs, a category that includes 
the following therapeutic classes: cough suppressants, 
expectorants, and mucolytics (Sharfstein et al., 2007). 
In primary health care, physicians often prescribe these 
drugs as the first line of treatment for acute cough (Smith 
et al., 2008).
Since the 1980s, evidence about the efficacy and 
safety of acute cough drugs has been called into question in 
the literature (Smith et al., 2008; Woo, 2008; CDC, 2007; 
Heineck et al., 1998; Rozenfeld et al., 1989). In 2006, the 
American College of Chest Physicians published nine 
guidelines for treating acute cough, which do not recom-
mend use of OTC drugs (Bolser, 2006). Another concern 
regarding cough medications is fixed-dose combinations 
because using two or more drugs in the same formulation, 
besides having no supporting therapeutic grounds or scien-
tific evidence, increases the risk of adverse events (Woo, 
2008; Cadime, 2000).
The National Health Surveillance Agency (Agência 
Nacional de Vigilância Sanitária -ANVISA) was esta-
blished in the late 1990s and brought about significant 
changes in the regulatory process of medications for sale 
in Brazil. Nevertheless, the national market offers an 
excessive number of drugs, with a significant number of 
pharmaceuticals of questionable or zero value, which are 
commercialized in different drug dosage forms and packa-
ging, in a context of high prevalence of self-medication 
(Rinovato, 2008; Osório-De-Castro, 2000). These market 
conditions, in addition to the aggressive marketing actions 
by the pharmaceutical industry, allow medications to be 
used inappropriately, which can cause iatrogenic diseases 
and lead to higher costs to users and the health system.
In Brazil, cough medications are classified as OTC 
drugs, as per the list regulated by Resolution RDC number 
138, of 05/29/03 by ANVISA (Brasil, 2003). The studies 
that analyzed the quality of cough medications sold in 
Brazil were published before ANVISA was established 
(Heineck et al., 1998; Rozenfeld et al., 1989).
The objective of this study was to learn about the 
current situation with respect to cough medications re-
gistered in Brazil, analyze the evidence for these drugs’ 
efficacy and safety, and discuss the risks associated to their 
sale as OTC drugs.
METHODOLOGY
This is a drug utilization study, which analyzes the 
supply for acute cough drugs using the ANVISA database 
for drugs and hemoderivatives. Drugs supply studies pro-
vide analysis of the therapeutic quality of the drugs avai-
lable in a given country or region, based on information 
from the pharmaceutical products registration system or 
national catalogs (Laporte, Tognoni, 1993). 
The first step of this investigation was to perform a 
bibliographic search of tertiary international pharmacothe-
rapy sources to identify the cough drugs used in clinical 
practice. The review was performed using the Handbook 
of Nonprescription Drugs 14ed and Martindale: The 
Complete Drug Reference 34ed (Sweetman, 2005, Be-
rardi, 2004). The cough medicines included in this study 
were single-drug preparations or combinations of cough 
suppressants, expectorants and mucolytics. The identified 
drugs were grouped according to the Anatomic Therapeu-
tic Chemical Classification System (ATC) to sublevel 4 
as follows: RO5CA - expectorants, RO5CB - mucolytics, 
R05DA-opium alkaloids, R05DB – other cough suppres-
sants, R05FA – combination of opium derivatives and 
expectorants, and R05X – other combinations. The second 
step was to identify the common Brazilian name for the 
drugs based on the List of Common Brazilian Denomina-
tions (CBD, 2007; Brasil, 2007). The existence of the iden-
tified drugs was verified using the electronic database of 
“registered drugs and hemoderivative products” available 
on the ANVISA website. The ANVISA database used in 
the research was updated after 3/25/2002 (Brasil, 2008a). 
Drug registrations were first searched based on the CBD. 
If drugs did not have a CBD, their names were translated 
to Portuguese to perform the search. Phytopharmaceuticals 
were searched using the scientific name of the botanic 
species from which the active substance is extracted. The 
search of the ANVISA database yielded information about 
the drug dosage form, drug combinations, and registered 
products. In this study, “formulation” refers to a single 
drug preparation or combination, apart from excipients. 
Drugs included in this study had registrations which were 
valid until May 2008.
The quality of the evidence of the drugs’ efficacy and 
safety was determined through a bibliographic search on 
PUBMED, Cochrane Library and SIETES (System of Es-
sential Information in Therapeutics and Health; database 
in Spanish). Studies were selected if they addressed the 
efficacy, safety, and effectiveness of drugs used for treating 
acute cough. Only drugs with medications registered in 
Brazil were included in the study. The information regar-
ding the drugs’ registration in the ANVISA database was 
listed using a data collection instrument. The information 
was then transferred to a database created using Epi Data 
3.1. Double entry was used and the obtained database 
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was validated and its consistency confirmed. Descriptive 
statistical analysis was performed using SPSS 15.0.
RESULTS
The therapeutic arsenal for treating acute cough 
identified in the pharmacology and therapeutic digests 
consisted of 107 drugs, 19 of which were active principles 
of medications registered in Brazil. There are 40 medica-
tion formulations registered in Brazil for cough treatment. 
The classification of the cough drug formulations 
registered in Brazil according to ACT level 4 is presented 
in Table I.
The cough drug formulations registered in Brazil 
consisted of 25 (62.5%) fixed-dose combinations and 15 
(37.5%) single drug preparations (Figure 1). Among the 
fixed-dose combinations, 8 (32%) used two drugs and 17 
(68%) used more than two drugs.
With regard to the composition of the formulations, 
it was observed that 19 (47.5%) were synthetic drug 
combinations, twelve (30.0%) were synthetic single drug 
preparations, three (7.5%) were phytopharmaceuticals, 
five (12.5%) were combinations of phytopharmaceuticals 
and synthetic drugs and one (2.5%) was a combination of 
multiple phytopharmaceuticals. The therapeutic classes of 
the fixed-dose combination drugs are presented in Table 
II, which shows there is a vast variety, with the expec-
torant guaifenesin appearing in the greatest number of 
pharmaceutical products as a component of combination 
formulations.
In terms of their drug dosage form, most (77.1%) 
medications containing cough drugs were liquids. Other 
common drug dosage forms were lozenges and pills.
Table III shows the number of pharmaceutical pro-
ducts registered per formulation, regardless of the different 
presentations of each manufacturer. It is evident that most 
formulations (23; 57.5%) had only one registered pharma-
ceutical products, and that nine formulations (22.5%) had 
registers for over five medications.
The bibliographic search performed on PubMed 
found studies related to the treatment of acute cough that 
used five of the drugs registered in Brazil. The review 
on the Cochrane database found two clinical studies 
involving two of these drugs. On SIETES, in addition to 
clinical studies, drug surveillance warnings and a review 
of adverse reactions to dextromethorphan were found. The 
characteristics of the studies found on the cited databases 
FIGURE 1 -Therapeutic arsenal for treating acute cough.
TABLE I – ATC sublevel 4 classification of cough treatment formulations registered in Brazil
Classification and drugs N %
R05CA - Expectorants:
Glycyrrhiza glabra, Guaifenesin, Hedera helix
Potassium iodide, Mikania glomerata spreng., Potassium Sulfa Guayacolato 
6 15
R05CB – Mucolytics:
Acetylcysteine, Ambroxol, Bromhexine, Carbocisteine
 4 10
R05DA – Opium alkaloids: 
Dextromethorphan
1 2.5
R05DB – Other cough suppressants
Clobutinol, Dropropizine, Cloperastine fendizoate, Levodropropizine
4 10
R05FA – Combination of opium derivatives and expectorants 
Dextromethorphan Bromhydrate + guaifenesin
1 2.5
R05X – Other combinations 24 60.0
Total 40 100
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TABLE II – Types of fixed-dose combinations for cough treatments registered in Brazil
Types of combinations Number of Registered 
Products
Combinations with antihistamines
Dextromethorphan Bromhydrate + Doxylamine succinate 1
Diphenhydramine hydrochloride + Ammonium chloride + Sodium citrate 2
Butamirate citrate + Oxeladin citrate + Diphenhydramine hydrochloride + Guaifenesin 1
Clobutinol + Doxilamine 5
Sodium dipyrone + Caffeine +Guaifenesin +Mepyramine maleate + Ascorbic acid 1
Teofilin + Guaifenesin +Pyridoxine +Diphenhydramine hydrochloride 1
Combinations with Adrenergic agents 
Guaifenesin + Dexchlorpheniramine maleate + Pseudoephedrine sulphate 5
Pseudoephedrine hydrochloride + Guaifenesin 3
Dexchlorpheniramine maleate + Ephedrine sulphate + Guaifenesin 1
Guaifenesin + Salbutamol sulphate 2
Salbutamol sulphate +Guaifenesin +Sodium citrate 1
Combinations with Potassium Iodide 
Sodium benzoate + Oxomemazine hydrochloride+Guaifenesin +Potassium iodide + Fluid extract* 1
Guaifenesin + Potassium iodide 1
Potassium iodide + Potassium Sulfa Guayacolato + Myroxylon balsamum harms 1
Potassium iodide + Menthol 1 
Potassium iodide +Guaifenesin +Menthol 1
Combinations with Phytopharmaceuticals 
Menthol + camphor + eucalyptol +essence* + essence* + lamiaceae essence + turpentine essence 
+terpineol
1
Nasturtium officinale br.+ Aconitum napellus + Mikania glomerata spreng. + Polygala senega + 
Cephaëlis ipecacuanha (brot) A.rich. + Myroxylon balsamum harm 
1
Tiocholine + Sodium dibunate+ Sodium benzoate + Fluid extract* + Fluid extract * + Aconitum 
napellus extract 
1
Other Combinations
Cetylpyridinium + Ammonium chloride + Sodium citrate + Sodium benzoate 1
Ammonium chloride + Cetylpyridinium hydrochloride 1
* not specified on the ANVISA database
TABLE III - Number of registered pharmaceutical products per cough therapy formulation
Number of registered 
products
Frequency Single drug 
preparations
Frequency 
Combinations 
Frequency Total Percentage
1 5 18 23 57.5
2 - 3 3 7.5
3 1 3 4 10
4 1 - 1 2.5
5-10 4 1 5 12.5
11-20 1 - 1 2.5
Over 20 3 - 3 7.5
Total 15 25 40 100
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are shown in Table 4. A meta-analysis of clinical trials with 
dextromethorphan (Pavezi, et al., 2001) was also found, in 
addition to four systematic reviews of clinical trials with 
general cough drugs (Smith et al., 2008; Schroeder, Fahey, 
2002a; Schroeder, Fahey 2002b; Schroeder, Fahey, 2004 ). 
The Cochrane systematic review (Schroeder, Fahey, 2004) 
included a randomized clinical trial with bromhexine whi-
ch was not identified in the electronic databases. No other 
clinical studies with the combinations registered in Brazil 
were found in the databases used in this study. 
DISCUSSION
A variety of active principles are available for 
clinical use in cough drugs. In Brazil, the therapeutic 
arsenal includes 19 drugs, which correspond to 17.7% of 
the potential substances available in these groups, 15 of 
which are present in the formulations with a single active 
principle (Figure 1). The number of formulations (40) 
and the presence of nine formulations with more than five 
registers, three of which have more than twenty registers 
(Table III), demonstrate the commercial importance of 
this group of medications, which represents a significant 
share of the pharmaceutical market according to estimates 
obtained in the United States (Sharfstein et al., 2007). 
In the 1980s, the single-drug preparations for cough 
treatment sold in Brazil were identified in a study based 
on the Pharmaceutical Products Dictionary (Dicionário 
de Especialidades Farmacêuticas -DEF)and comprised 15 
drugs. However, the number of drugs used in combinations 
was not stated. It is not possible to perform quantitative 
comparisons and evaluate the extent to which the availa-
bility of these drugs in the market has changed because 
this study used a different method for data collection that 
the present study. The national drug registration system is 
the most comprehensive for ascertaining the therapeutic 
arsenal because it is not economically biased. The DEF is 
a print publication and the availability of some informa-
tion depends on payment from pharmaceutical industries 
(Schulz et al., 2006). Furthermore, the present study in-
cluded phytopharmaceuticals, unlike the study performed 
in the 1980s. 
TABLE IV - Types of publication on the efficacy, safety and effectiveness of cough drugs registered in Brazil identified on Cochrane, 
Medline and SIETES database systems
Drug Type of publication Database Author(s), year
Acetylcysteine Observational study: 
pharmacoepidemiological
Medline Chalumeau et al., 2002
Drug surveillance warning SIETES Anónimo, 1997
Ambroxol Observational study: 
drug surveillance after 
commercialization 
Medline Schulz et al., 2006
Carbocysteine Observational study: Medline Chalumeau et al., 2002
Pharmacoepidemiological
Guaifenesin Randomized Clinical Trial Cochrane 
Medline 
Kuhn ,1982
Robinson et al., 1977
Dextromethorphan Randomized Clinical Trial
Meta-analysis
Cochrane
Medline 
Medline
Tukiainem et al.l, 1986
Taylor et al., 1993
Lee et al., 2000
Paul et al., 2004
Paul et al., 2007
Pavezi, et al., 2001
Randomized Clinical Trial SIETES Paul et al., 2007
Literature Review SIETES Thanacoody, 2007
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Regarding the therapeutic classes of the formula-
tions registered in Brazil according to ATC level 4 (Table 
I), there is a prevalence of other combinations for cough 
treatment (60.0%), but the following classes are also in-
cluded: expectorants (15.0%), mucolytics (10%) and other 
cough suppressants (10%). The most frequent type of com-
bination involves synthetic drugs (47.5%), but there are 
also combinations of phytopharmaceuticals and synthetic 
drugs (12.5%) as well as phytopharmaceuticals (2.5%).
There is much concern regarding the considerable 
number of drug combinations used for cough treatment, 
as literature reviews present no evidence supporting the 
use of any of the numerous combinations found on the 
Brazilian market (Tables I and II). On the other hand, it 
is known that the physiology of coughing contraindicates 
the use of any drugs containing cough suppressants com-
bined with expectorants or mucolytics, since there is no 
justification for combining a cough reflex inhibitor with 
drugs that require that same reflex to be preserved for their 
pharmacological action to take place (Bolser, 2006). 
The drug combinations for cough treatment need 
stronger grounds and evidence since they have not been 
evaluated through clinical trials with adequate internal and 
external validity to support their clinical use. The commer-
cialization of these substances as OTC drugs promotes the 
false perception that they are safe and efficacious. Drug 
combinations and other cough drugs of different classes 
often contain antihistamines, iodides, adrenergic or antimi-
crobial agents in their formulations. The uncontrolled use 
of these combinations is not devoid of risk. For example, 
antihistamine agents can cause drowsiness and reduce 
one’s ability to drive, whereas adrenergic agents can be 
dangerous in people with hypertension, hyperthyroidism, 
and coronary, cerebral, or peripheral artery diseases (Ca-
dime, 2000). Iodides are associated with an array of side 
effects, with extra caution required in specific age groups 
(children, and women who are pregnant or breastfeeding). 
Iodides are contraindicated in tuberculosis and their use is 
supported by relatively weak evidence that does not justify 
their commercialization as expectorants or use in combi-
nation with nonprescription antitussive drugs (Rozenfeld 
et al., 1989). Another concern, especially in chronic use, is 
that these combinations can interact with other drugs that 
the patient might be using (Cadime, 2000). 
The combinations of guaifenesin + pseudoephedrine 
and guaifenesin + pseudoephedrine + dexchlorphenirami-
ne maleate occur in the formulations used in the greatest 
number of registered pharmaceutical products. No studies 
on their safety and effectiveness were found, but the stu-
dies by the Centers for Disease Control and Prevention on 
cough and cold drugs and emergency room visits identified 
deaths of children related to the use of pseudoephedrine 
in fixed-dose combinations (Sharfstein et al., 2007; CDC, 
2007). The use of this drug is also associated with cardiac 
arrhythmias and other cardiovascular events (CDC, 2007). 
The availability of these over-the-counter combinations in 
the Brazilian market, which have no restrictions against 
use in children younger than two years, should be evalu-
ated to assess the public health risks.
In Brazil, 77.1 % of the registered cough drugs are 
sold in liquid form (Table II); this high incidence of liquid 
preparations, especially syrups, mirrors reports in other 
countries (Schulz et al., 2006). It was noted that 42.5% 
presently have a pending registry by more than one labo-
ratory and some products have up to 20 pending registries 
(Table III). This data confirms the previous statement that 
the cough drug classification is of great commercial inte-
rest for the pharmaceutical industry. 
Randomized clinical trials on acute cough treatment 
were identified only for dextromethorphan and guaifenesin 
(Table IV). A clinical trial for bromhexine was found among 
the studies included in the systematic review (Schroeder, 
Fahey, 2004). The methodological quality of the studies 
of this and other antitussive agents not sold in Brazil was 
evaluated in four published systematic reviews (Smith et al., 
2008; Schroeder, Fahey, 2002a; Schroeder, Fahey, 2002b; 
Schroeder, Fahey, 2004). Reviews published in 2004 and 
2008 on Cochrane included the meta-analysis of clinical 
trials of dextromethorphan performed by Pavesi et al., 2001.
The Cochrane reviewers stated that clinical studies 
conducted on nonprescription cough drugs present the 
following issues: small samples, inadequate masking stra-
tegies, lack of clarity of methods used to measure results, 
poor reporting of results, absence of placebo comparison, 
comparison of different therapeutic classes, and lack of 
uniformity in terms of cough duration in the patient inclu-
sion criteria (Smith et al., 2008; Schroeder, Fahey, 2004 ).
In view of the quality of the clinical trials, the 
systematic reviews did not find any negative or positive 
evidence for indication of these drugs in acute cough. The 
2008 version reiterates that their value in cough treatment 
remains inconclusive and confirms the lack of evidence 
for their effectiveness. It highlights the methodological 
limitations of the clinical trials performed on this drug 
class and suggests performing further studies to improve 
these aspects to better clarify the drugs’ effectiveness and 
safety (Smith et al., 2008).
It is imperative that clinical trials of cough drugs 
be performed using a design that complies with quality 
clinical research practice, using validated instruments to 
evaluate cough and its consequences, so as to elucidate 
the efficacy of these drugs. These actions are important to 
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avoid creating clinical guidelines based more on opinions 
than on evidence, as has occurred with guidelines publi-
shed recently by the American College of Chest Physicians 
(Chung, 2007).
A clinical trial that evaluated dextromethorphan, 
honey and placebo in cough treatment in children (Paul et 
al., 2007) was published after the last systematic review. 
This study is notable because it provides new perspectives 
for cough treatment, since it found that honey was superior 
to Dextromethorphan or placebo in cough treatment in 
children with mild airway infections associated with sleep 
difficulties. Further studies are needed because the study in 
question was performed on a single day without complete 
double masking, and data collection was performed by the 
children’s parents using a subjective questionnaire (La-
porte et al., 2007). Eccles, in 2006, published physiologic 
explanations to justify the action of honey and other sweet 
substances on productive and dry coughs. The author used 
these probable action mechanisms to further infer that in 
liquid antitussive drugs, the sweet-tasting excipients were 
not inert and, therefore studies are unable to detect any sig-
nificant difference in relation to placebos. Further studies 
with appropriate experimental models and supplemented 
with clinical trials performed based on quality clinical 
study practices can clarify this hypothesis and determine 
the therapeutic value of honey and other sweet substances 
on cough treatment.
The study of carbocisteine and acetylcysteine entai-
led an observational pharmacoepidemiological investiga-
tion performed with a sample of prescriptions by French 
pediatricians. It was found that 4.3% of prescriptions 
included mucolytic agents. The main indications were 
rhinopharyngitis, cough and acute bronchitis. Based on 
a literature review, the study concluded that the efficacy 
of these mucolytics in children was unclear. The study 
authors warned that the data from the French drug sur-
veillance system indicated these drugs were unsafe in 
children due to the risk of paradoxical bronchoalveolar 
congestion (Chalumeau et al., 2002).
A post-marketing drug surveillance study involving 
2664 participants selected at 266 German pharmacies eva-
luated the safety and utilization pattern of ambroxol syrup 
using a self-administered questionnaire. The adverse drug 
reaction (ADR) report rate was 2.5%, and most adverse 
reactions were associated with the digestive system. No 
serious or unknown ADRs were reported. Ambroxol safety 
was considered very good by 51% of users and good by 
46%. Regarding its effectiveness, 29% considered it very 
good and 63% good, with 89% of users reporting they 
would use the drug again if needed. The study concluded 
that the use of OTC drugs can be controlled by pharmacies 
and that in Germany, ambroxol is used in compliance with 
the medicine package inserts. The study highlighted that 
the drug’s safety and efficacy for acute bronchitis was 
confirmed (Schulz et al., 2006). The study has many me-
thodological limitations, especially concerning the analy-
sis, since it does not present the results according to the 
type of cough. In the discussion, the study stated that the 
product was used as a self-administered cough drug, but 
in the conclusion section it presented conclusions based 
exclusively on acute bronchitis. To justify the statement 
about the drug’s safety and efficacy, the authors made 
reference to studies performed on patients with chronic 
respiratory system diseases. However, the fact that this 
study used patients’ statements for adverse reaction re-
ports remains controversial in terms of drug surveillance 
(Harmark, Grootheest, 2008).
The search on the SIETES database found publica-
tions on the safety of acetylcysteine and dextromethor-
phan. This particular database specializes in information 
on medications and contained drug surveillance warnings 
and studies not indexed on the PubMed database. These 
studies are important sources for the evaluation of the 
risk-benefit relationship of the drugs available on the ma-
rket and are therefore relevant for studies on drug supply. 
The adverse reactions described in these studies can be 
serious, including hypersensitivity to acetylcysteine, and 
serotonergic syndrome after dextromethorphan (Anónimo, 
1997; Thanacoody, 2007)
The results of the systematic reviews, the small 
number of observational studies, the reported adverse reac-
tions, and the quality of the clinical trials call for a critical 
analysis of the classification of OTC drugs for acute cough 
treatment. This analysis should be performed considering 
the theoretical criteria that should support the approval of a 
drug for sale without a prescription. Strom (2005) identified 
important criteria to make the registration of OTC drugs 
feasible. First, the drug’s safety and effectiveness should be 
well established. Another essential condition is to determine 
the efficacy of the self-diagnosed clinical condition. The 
drug should have a broad margin of safety established for a 
considerable number of individuals. The drug should have 
a low potential for abuse and low risk for inadequate use 
or drug interactions. Efficacy and safety should not depend 
primarily on the dose or frequency of administration. The 
drug should be safe for use by special populations such as 
pregnant women, aged individuals and children. The author 
presents supplementary criteria, mainly regarding patient 
information on self-diagnosis and self-treatment.
Drugs for acute cough do not meet the main criteria: 
safety and effectiveness for the symptoms that led to their 
use. In addition, these drugs do not have a broad margin 
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of safety for a considerable number of individuals (Smith 
et al., 2008). Another flaw is the failure to establish the 
efficacy for the self-established clinical condition. In fact, 
the section in which the 2008 systematic review suggests 
further studies, carries a recommendation evidencing that 
this criterion was not met by the drug group. Dextrome-
thorphan presented a potential for abuse, since it is used 
as a recreational drug, mainly among adolescents (Bryner, 
2006; Falck, 2006; Paul et al., 2004). The profile of the 
adverse reactions to antitussive agents is widely discussed 
in the medical literature. Dextromethorphan in therapeutic 
doses can cause the following: dystonia, bullous mas-
tocytosis and anaphylaxis while at high doses it can cause, 
among other reactions, hallucination, ataxia, psychosis, 
cerebral degeneration and peripheral neuropathy (Paul 
et al. , 2007). The safety of cough drugs in children less 
than two years of age is not yet well established, and the 
pediatric doses have been obtained by extrapolation from 
the adult doses (CDC, 2007). Emergency care provided to 
children less than twelve years of age due to adverse events 
associated with antitussive agents is an issue of concern in 
the United States (Schaefer et al., 2007). It is evident that 
cough drugs do not fully satisfy the minimum requisites 
for being sold over the counter. 
The withdrawal of clobutinol from the market in se-
veral countries by its manufacturer, and the Food and Drug 
Administration (FDA) recommendation not to use anti-
tussive and cold drugs in children younger than two years 
of age, are concrete actions of a pharmaceutical industry 
and regulating agency that show flaws in the registration 
of OTC drugs which potentially expose the population to 
risk (FDA, 2008). Clobutinol is associated with a risk of 
QT interval prolongation which can cause cardiotoxicity 
(WHO, 2008). The flawed nature of OTC drug registration 
became more evident when it was verified that generic 
clobutinol is still sold in Brazil despite the reference drug 
being withdrawn from the market. The restriction on the 
use of antitussive agents in children younger than two 
years was motivated by the absence of any evidence of its 
efficacy, a lack of consensus on the pediatric dose, and the 
risks associated with morbidity and mortality in this age 
group (CDC, 2007; Irwin, 2007). The technical reports 
announced on the ANVISA website do not include any 
warnings restricting the use of cough drugs in children 
younger than two years (Brasil, 2008b).
In the light of these flaws in the criteria for registe-
ring OTC drugs, it is important to know the therapeutic 
value of the drugs available on the country’s market. An 
analysis of the main OTC drugs sold in Brazil in the 1990s 
showed that 91% had poor intrinsic value. The sample 
included antitussive agents and expectorants, which were 
classified as having little or no value (Heineck et al., 
1998). A study on cough drugs found there was a lack of 
scientific evidence regarding their efficacy coupled with a 
high rate of drug combinations (Smith et al., 2008). These 
characteristics are similar to drugs currently registered 
in Brazil. In view of these conditions and the culture of 
self-administration, it is essential to implement measures 
to improve the registration process as well as the drug 
surveillance actions aimed at OTC drugs. The reporting 
pharmacies program under development by ANVISA is a 
step toward making drug surveillance practices feasible 
in this drug group. 
Health surveillance actions related to drug ma-
nagement should be grounded in scientific studies that 
evaluate the collective risk-benefit. This practice can con-
tribute to the quality of the drug registration process and 
the monitoring of the safety of pharmaceutical products 
sold in Brazil. Therefore, the results of studies on cough 
drugs, especially those published by the CDC (2005) 
and Cochrane (Smith et al., 2008) indicate the need for 
ANVISA to reevaluate the decision of maintaining these 
drug groups on the Brazilian market, considering the risk-
benefit relationship. A review on the registrations of cough 
drugs, especially combinations, is essential to guarantee 
the availability of safe and effective pharmaceuticals on 
the national market.
The development of educational material on strate-
gies to cope with acute cough for the lay population, as 
well as the dissemination of information to prescribers 
about the scientific evidence regarding treatment, are me-
asures that contribute toward the safe use of these drugs.
One limitation of the present study was the use of a 
database that provides information exclusively for registe-
red drugs. Therefore, it cannot be stated that all these drugs 
are currently available on the Brazilian market. However, 
it is possible to gain insights into the qualitative profile of 
registered drugs and, indirectly, about the fragility of the 
criteria used for registration. Further studies, using private 
databases specialized for the pharmaceutical market, or 
other ANVISA databases, will enable identification of the 
drugs that are truly being sold in Brazil as well as their 
economic relevance.
In addition, further studies available on the ANVISA 
adverse drug reactions database and the national poisoning 
information system can improve knowledge about the 
safety profile of these drugs in Brazil.
CONCLUSION
The efficacy and effectiveness of cough drugs 
available on the Brazilian market is poorly supported 
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by weak evidence. There is much concern regarding the 
considerable number of combined preparations containing 
antitussive agents and over the lack of restrictions on the 
use of these drugs in children under two years of age. To 
summarize, there is no evidence supporting the recommen-
dation of these drugs as the first-line treatment for acute 
cough associated with upper respiratory tract infections.
The intrinsic therapeutic value of drugs sold in Bra-
zil is similar to that of drugs available in the late 1980s, 
which suggests that the new registration systems imple-
mented in the country through ANVISA did not affect the 
qualitative profile of this drug group. 
The present study on drug supply provides informa-
tion about the profile of drugs used for cough treatment 
registered in Brazil, and on the implementation of regula-
tory and educational measures with a view to assuring the 
rational use of these drugs. The study results also highlight 
the need to reevaluate the registration criteria for OTC dru-
gs, with the purpose of guaranteeing that individuals who 
choose self-medication have access to safe and effective 
drugs. It is essential to make pharmacovigilance actions 
feasible for OTC drugs in order to establish the risk-benefit 
relationship of this therapeutic class.
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